데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다
154229-19-3CC12CCC(O)CC1=CCC1C2CCC2(C)C(c3cccnc3)=CCC12154229-19-3CHEMBL2138202White Solid
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
역사Abiraterone (brand name: Zytiga) is an anti-cancer drug developed by Centocor Ortho Biotech Inc. It was first approved by the FDA on 28 April 2011 for the treatment of advanced prostate cancer. In December 2012, the FDA expanded Zytiga's approved use to include treatment of men with advanced (metastatic) castration-resistant prostate cancer prior to chemotherapy. By February 2018, the FDA further approved Zytiga (abiraterone acetate) in combination with prednisone for the treatment of early metastatic prostate cancer.
용도Abiraterone, a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), is currently undergoing phase II clinical trials as a potential drug for the treatment of androgen-dependent pr ostate cancer.
불러오는 중…
정의ChEBI: A 3beta-sterol that is androsta-5,16-dien-3beta-ol substituted at position 17 by a 3-pyridyl group. Administered as the O-acetate, it is used for treatment of metastatic castrate-resistant prostate cance .